191 related articles for article (PubMed ID: 20399911)
1. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
4. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
5. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
7. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia S; Montgomery JA; Johnson HG; Walsh GM
Immunopharmacology; 1996 Oct; 35(1):53-63. PubMed ID: 8913795
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
10. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
Conry RM; Bantia S; Turner HS; Barlow DL; Allen KO; LoBuglio AF; Montgomery JA; Walsh GM
Immunopharmacology; 1998 Jul; 40(1):1-9. PubMed ID: 9776473
[TBL] [Abstract][Full Text] [Related]
11. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
12. The effect of deoxyguanosine on human lymphocyte function. II. Analysis of the interference with B lymphocyte differentiation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Duran M; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2318-23. PubMed ID: 6425400
[TBL] [Abstract][Full Text] [Related]
13. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
14. Effects of purine nucleoside phosphorylase deficiency on thymocyte development.
Papinazath T; Min W; Sujiththa S; Cohen A; Ackerley C; Roifman CM; Grunebaum E
J Allergy Clin Immunol; 2011 Oct; 128(4):854-863.e1. PubMed ID: 21868080
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction.
Sharma KG; Radha R; Pao A; Amet N; Baden L; Jordan SC; Toyoda M
Transpl Immunol; 2010 Jul; 23(3):117-20. PubMed ID: 20450974
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
Kilpatrick JM; Morris PE; Serota DG; Phillips D; Moore DR; Bennett JC; Babu YS
Int Immunopharmacol; 2003 Apr; 3(4):541-8. PubMed ID: 12689658
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan DS; Nagashima T; Hoshino T; Waldman F; Pawlak K; Sadee W
Biochem J; 1990 Jun; 268(3):725-31. PubMed ID: 2114100
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of deoxyguanosine by B and T lymphocytes: evidence against selective trapping of deoxyguanosine by T lymphocytes in purine nucleoside phosphorylase deficiency.
North ME; Newton CA; Webster AD
Clin Exp Immunol; 1980 Dec; 42(3):523-9. PubMed ID: 6783354
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
